Sponsored Content

There may be some hope yet for sufferers of glioblastoma, an extremely aggressive type of brain cancer for which there is no cure.

New research from MGC Pharma (ASX:MXC) in conjunction with Slovenia’s National Institute of Biology and University Medical Centre Ljubljana, has shown certain cannabinoid formulations can inhibit tumour growth as well as cause cancer cell death.

At a glance

  • Glioblastoma is the most aggressive brain cancer for which the survival rate is very low — fewer than 5 per cent of patients survive longer than five years
  • Cannabinoid formulations were shown to have the ability to target glioblastoma stem cells that are considered to be the roots of the disease and the critical target in oncology therapy
  • MGC will continue to develop the research and look to translate the pre-clinical and lab results into humans

Glioblastoma is most commonly treated with surgery, chemotherapy (using the drug temozolomide) and radiation, but many patients to respond to temozolomide, as NHMRC senior research fellow Stuart Pitson at the University of South Australia explained at The Conversation.

But Professor Tamara Lah Turnšek of the National Institute of Biology, said there was new hope thanks to the cannabinoid formulations, the intellectual property of MGC Pharma.

“Evidence has demonstrated that cannabinoids inhibit growth in invasiveness of tumour cells and continues to be solidified, based on cellular experiments in vitro and in animal studies,” she said.

“The modern treatment modalities, surgical removal, irradiation and chemotherapy can be supported or even replaced by adjuvant treatment strategies, including cannabinoids.”

More on MGC Pharma

MXC’s medical cannabis dementia trial goes live

MXC products available in the growing UK medical cannabis market

MXC supercharges commercial strategy with retargeted focus on two core business divisions

About MGC Pharma

MGC Pharmaceuticals Ltd (ASX: MXC) is a European-based seed-to-pharmacy biopharma company with many years of technical clinical and commercial experience in the medical cannabis industry.

The company’s founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality cannabinoids-based pharmaceuticals products for the growing demand in the medical markets in Europe, North America and Australasia.

This content is produced by Star Investing in commercial partnership with MGC Pharmaceuticals. This content does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.